Shaping of adaptive immune responses to soluble proteins by TLR agonists:: A role for IFN-α/β

被引:82
作者
Durand, V [1 ]
Wong, SYC [1 ]
Tough, DF [1 ]
Le Bon, A [1 ]
机构
[1] Edward Jenner Inst Vaccine Res, Newbury RG207NN, Berks, England
关键词
cross-priming; cytokines; interferon-alpha/beta; IgG2a; pro-inflammatory; toll-like receptors;
D O I
10.1111/j.0818-9641.2004.01285.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Toll-like receptors (TLR) are believed to play a major role in the recognition of invading organisms, although their ability to shape immune responses is not completely understood. Our aim was to investigate in vivo the effect of different TLR stimuli on the generation of antibody responses and the induction of CD8(+) T-cell cross-priming after immunization with soluble protein antigens. While all TLR agonists tested elicited the production of immunomodulatory cytokines, marked differences were observed in their ability to stimulate antigen-specific immune responses. Zymosan, poly(I:C) and CpG DNA, which signal through TLR2/6, 3 and 9, respectively, were found to strongly induce the production of IgG2a antibodies, whereas R-848 (TLR7) and LPS (TLR4) did so much more weakly. In contrast, LPS, poly(I:C) and CpG DNA, but not zymosan, induced functional CD8(+) T-cell responses against OVA; peptidoglycan (TLR2/?) and R-848 were also ineffective in stimulating cross-priming. Experiments using IFN-alpha/betaR-deficient mice showed that the induction of cross-priming by LPS and poly(I:C) was abrogated in the absence of IFN-alpha/beta signalling, and induction by CpG DNA was greatly reduced. Overall, our results identify LPS as another TLR agonist that is able to generate functional cross-priming against a soluble protein antigen. In addition, our results demonstrate that the ability of TLR stimuli to initiate CD8(+) T-cell responses against soluble protein antigens is largely dependent on the IFN-alpha/beta signalling pathway.
引用
收藏
页码:596 / 602
页数:7
相关论文
共 19 条
  • [1] Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN
    Ahonen, CL
    Doxsee, CL
    McGurran, SM
    Riter, TR
    Wade, WF
    Barth, RJ
    Vasilakos, JP
    Noelle, RJ
    Kedl, RM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (06) : 775 - 784
  • [2] Mammalian Toll-like receptors
    Akira, S
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (01) : 5 - 11
  • [3] Toll-like receptors: critical proteins linking innate and acquired immunity
    Akira, S
    Takeda, K
    Kaisho, T
    [J]. NATURE IMMUNOLOGY, 2001, 2 (08) : 675 - 680
  • [4] Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism
    Cho, HJ
    Takabayashi, K
    Cheng, PM
    Nguyen, MD
    Corr, M
    Tuck, S
    Raz, E
    [J]. NATURE BIOTECHNOLOGY, 2000, 18 (05) : 509 - 514
  • [5] Toll-like receptor 3 mediates a more potent antiviral response than toll-like receptor 4
    Doyle, SE
    O'Connell, R
    Vaidya, SA
    Chow, EK
    Yee, K
    Cheng, GH
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (07) : 3565 - 3571
  • [6] Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon
    Le Bon, A
    Etchart, N
    Rossmann, C
    Ashton, M
    Hou, S
    Gewert, D
    Borrow, P
    Tough, DF
    [J]. NATURE IMMUNOLOGY, 2003, 4 (10) : 1009 - 1015
  • [7] Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo
    Le Bon, A
    Schiavoni, G
    D'Agostino, G
    Gresser, I
    Belardelli, F
    Tough, DF
    [J]. IMMUNITY, 2001, 14 (04) : 461 - 470
  • [8] Toll-like receptors control activation of adaptive immune responses
    Schnare, M
    Barton, GM
    Holt, AC
    Takeda, K
    Akira, S
    Medzhitov, R
    [J]. NATURE IMMUNOLOGY, 2001, 2 (10) : 947 - 950
  • [9] Role of Toll-like receptors in costimulating cytotoxic T cell responses
    Schwarz, K
    Storni, T
    Manolova, V
    Didierlaurent, A
    Sirard, JC
    Röthlisberger, P
    Bachmann, MF
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (06) : 1465 - 1470
  • [10] Sousa CRE, 2001, IMMUNITY, V14, P495